Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Recruiting

• Conditions: Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Hormone Receptor-Positive Breast Carcinoma

• Registration Number: NCT06106282
• Lead Sponsor: Mayo Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-24
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

Inclusion Criteria:<br><br> - Patients are 18 years old or more.<br><br> - A breast cancer survivor ECOG =< 2, stage 0-III HR+ who is experiencing<br> musculoskeletal symptoms associated with aromatase inhibitors intake<br><br> - Patients must be at least 6 months on aromatase inhibitors and for no more than<br> 7 years<br><br>Exclusion Criteria:<br><br> - Breast cancer survivor patients that are not in aromatase inhibitor treatment or<br> have less than 6 months of treatment or more than 7 years of treatment.<br><br> - Asymptomatic patients<br><br> - Patients less than 18 years old<br><br> - Patient that are not being followed as a Mayo Clinic patient<br><br> - Patients with stage IV breast carcinoma<br><br> - Patients that are HR -<br><br> - Patients that are ECOG 3 or more

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adherence to Aromatase Inhibitor (AI) treatment regimen;Functional impairment (quality of life);Fatigue;Level of pain;Mood